BREAKING NEWS: One-off Johnson & Johnson COVID-19 vaccine is LESS EFFECTIVE against Indian ‘Delta’ variant than Pfizer and Moderna injections, study suggests
- A new study looked at blood samples from patients who received the Pfizer, Moderna and Johnson & Johnson vaccine against the Indian ‘Delta’ variant
- Antibody levels in J&J patients were five to seven times lower when exposed to the Delta variant compared to three times lower in Pfizer and Modera patients
- This suggests that the 13 million Americans who received J&J need boosters to protect themselves from variants
The Johnson & Johnson COVID-19 vaccine is less effective against the Indian ‘Delta’ coronavirus variant than other injections, a new study suggests.
Researchers found that the antibody levels of people who received the single-dose vaccine were twice as low compared to those who received the two doses of Pfizer-BioNTech or Moderna vaccines.
The findings add to the growing body of evidence that the 13 million Americans who received J&J will need boosters to protect themselves against highly contagious strains.
It comes like Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), testified before the Senate Committee on Health, Education, Labor and Pensions on Wednesday that the variant makes up 83 percent of all new cases.
Antibody levels in people who received Johnson & Johnson’s COVID-19 vaccine were low against the Indian variant of the ‘Delta’ coronavirus. Pictured: Johnson & Johnson’s Covid-19 vaccines seen on a table in Los Angeles, May 2021
‘The message we wanted to give was not that people shouldn’t get the J.&J. vaccine, but we hope in the future it will be boosted with a new dose of J&J or a boost with Pfizer or Moderna,” said lead author Dr. Nathaniel Landau, a virologist at NYU’s Grossman School of Medicine. The New York Times.
For the study, which has not been peer-reviewed, researchers looked at blood samples from 27 patients.
Of the group, 17 people had been immunized with two doses of the Pfizer or Moderna vaccine and 10 people had been immunized with one dose of the J&J vaccine.
Researchers found that antibody levels in J&J patients were five to seven times lower when exposed to the Delta variant.
In comparison, levels in Pfizer and Moderna patients were three times lower.
The findings are consistent with a UK study, which found that the AstraZeneca vaccine – which is made with the same technology that the J&J vaccine uses – is 33 percent effective against symptomatic diseases caused by Delta.
This is a latest news item and will be updated.